Kadmon Holdings Inc. closed its previously announced offerings to raise about $113.2 million.

The total proceeds include funds raised due to underwriters fully exercising their option to buy additional shares.

The New York-based biopharmaceutical company plans to use the proceeds for preclinical and clinical development of its lead product candidates, as well as other general corporate purposes among others.

Jefferies LLC acted as sole book-running manager for the underwritten offering, with H.C. Wainwright & Co. LLC as lead manager.